Synairgen's Drug Shows Reduced Risk of Severe Disease in Covid-19 Patients

Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.

The preliminary, which utilized interferon beta, demonstrated that patients who were given Synairgen's detailing had a 79%



lower danger of creating extreme ailment contrasted with fake treatment.

Patients who received the drug, SNG001, were more than twice as likely to recover from COVID-19 as those on placebo, the company said.

Interferon beta is a naturally occurring protein, which regulates the body's antiviral responses.